Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Variant receptors challenge treatment strategies for prostate cancer
Key clinical point: Androgen receptors and the splice variant AR-V7 both regulated subsets of target genes and also induced alternative splicing of mRNAs in prostate cancer cells.
Major finding: A novel exon linked to exon 4 notably increased the induction of the PGAP2 gene by the androgen receptor variant known as AR-V7 to a 50-fold induction.
Study details: The data come from an examination of two endogenous genes, PGAP2 and TPD52, to determine their impact on splicing in prostate cancer cells using cell lines.
Disclosures: The study was supported by DAMD W81XWH-17-1-0236 and CPRIT RP150648 as well as by The Cancer Prevention Institute of Texas, the National Institutes of Health, and the National Institute of Environmental Health Sciences.
Rana M et al. Sci Rep. 2021 Jan 14. doi: 10.1038/s41598-021-81164-0.